Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Continuous dosing of BAY73-4506 in patients with advanced cancer

Phase 1

Bayer